We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Time and other considerations when evaluating a switch to newer drug formulations (eg, subQ vs IV).
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: